Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
5-HT2A-receptor Binding: Implications for the Pathophysiology of Schizophrenia and Effects of Treatment With Antipsychotic Drugs
Sponsor: AstraZeneca
A NA clinical study on Schizophrenia, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2004. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Birte Glenthoj
- Copenhagen Hospital Corporation
- Copenhagen University Hospital, Hvidovre
- Glostrup University Hospital, Copenhagen
- Rigshospitalet, Denmark
- The Danish Medical Research Council
- University of Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .